摘要
目的观察骨化三醇联合缬沙坦治疗IgA肾病的临床疗效。方法选取52例IgA肾病患者，随机分为联合治疗组和缬沙坦组，每组各26例，观察6个月。两组患者在治疗前后进行血压、尿蛋白、血肌酐、血清白蛋白、血钾、血钙、iPTH等测量或检测，并观察药物的不良反应。结果两组患者治疗后尿蛋白定量较治疗前均显著下降（P〈0．05），联合治疗组下降更明显（P〈0．01），联合治疗组与缬沙坦组比较，差异有统计学意义（P〈0.05）。两组患者在治疗期间均无严重不良反应。结论骨化三醇联合缬沙坦可有效降低IgA肾病患者蛋白尿，延缓疾病进展。
Objective To observe the clinical effect of calcitriol combined with valsartan in the treatment of IgA nephropathy. Methods 52 patients with IgA nephropathy were selected.All patients were randomly divided into valsartan group and combination therapy （ calcitriol＋ valsartan ） group.After treating for 6 months, the changes of blood pressure, urinary protein, renal function, serum albumin, serum potassium, serum calcium and iPTH were measured. Results Urine protein in the two groups after treatment decreased significantly compared with before treatment （P〈0.05） , and the combined treatment group decreased more significantly （ P〈0.01 ） .Compared to valsartan group, urine protein in combination therapy group was significantly decreased after 6 months （ P〈0.05 ） .There were no obvious adverse effects during the treatment in each group. Conclusion Combination therapy with calcitriol and valsartan can reduce urine protein excretion in IgA nephropathy patients.
出处
《浙江临床医学》
2018年第8期1407-1408,共2页
Zhejiang Clinical Medical Journal
